Role of rs 1800625 and 63bp deletion RAGE Gene Polymorphisms in Hepatocellular Carcinoma Progression

Abstract

Background: Hepatocellular carcinoma (HCC) is a common liver malignancy, whose heterogeneous occurrence indicates genetic dissimilarities between people in the main risk factors. Advanced glycation end product receptor (RAGE) is a multiligand receptor implicated in several pathogenic conditions, including cancer. In this study, the impact of RAGE gene polymorphisms on the susceptibility to hepatocarcinogenesis was explored. Aim of study: to estimate the effect of gene variations of RAGE on the progress of HCC caused by any viral infection and to examine the relationship between a RAGE and the risk and progression of HCC. Material and methods: single-nucleotide polymorphism (SNP; rs1800625) (-429T>C), and the 63 bp deletion (-407 to -345) in the 5’ flanking region of the RAGE gene were investigated among 90 HCV patients divided into 3 groups and 20 healthy controls. The HCV cases were diagnosed by polymerase chain reaction (PCR) while the HCC was diagnosed by Alfa-fetoprotein (AFP) test in addition to computed tomography. Liver cirrhosis was diagnosed with abdominal sonography. Results and conclusion: The study detected a significant association of rs1800625 with the increased risk of HCC also majority of HCC patient (86.7%) showed 63 bp deletion polymorphism (- 407 – 345 ) , our data suggest a correlation of RAGE gene polymorphism rs1800625 with the early stage of liver tumorigenesis and implicate its protective role in the progression of HCC.